Chemomab Therapeutics (NASDAQ:CMMB) Trading 0.7% Higher – What’s Next?

Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB)’s stock price rose 0.7% during mid-day trading on Friday . The company traded as high as $2.79 and last traded at $2.72. Approximately 165,423 shares traded hands during mid-day trading, an increase of 29% from the average daily volume of 128,348 shares. The stock had previously closed at $2.70.

Analyst Ratings Changes

CMMB has been the subject of a number of recent research reports. Oppenheimer upped their price objective on shares of Chemomab Therapeutics from $10.00 to $25.00 and gave the stock an “outperform” rating in a report on Wednesday, August 27th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Chemomab Therapeutics in a research note on Saturday, September 27th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $26.50.

Chemomab Therapeutics Stock Up 0.7%

The stock has a market cap of $14.06 million, a price-to-earnings ratio of -1.15 and a beta of 0.57. The company’s 50-day moving average is $3.30 and its 200-day moving average is $4.31.

Chemomab Therapeutics (NASDAQ:CMMB) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.80) by $0.44. On average, research analysts forecast that Chemomab Therapeutics Ltd. Sponsored ADR will post -1 earnings per share for the current year.

Institutional Trading of Chemomab Therapeutics

A hedge fund recently raised its stake in Chemomab Therapeutics stock. Virtu Financial LLC raised its position in shares of Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) by 113.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 30,803 shares of the company’s stock after buying an additional 16,358 shares during the period. Virtu Financial LLC owned about 0.21% of Chemomab Therapeutics worth $34,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 46.05% of the company’s stock.

About Chemomab Therapeutics

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).